Minerva Neurosciences Reports Third Quarter 2017 Financial Results and Business Updates
06 nov. 2017 07h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Provides Update on Phase 3 Design and Development Strategy for MIN-101
15 mai 2017 08h15 HE
|
Minerva Neurosciences, Inc.
Advancing a new potential therapeutic paradigm for the treatment of negative symptoms, a key unmet need in schizophrenia and other brain diseasesCompany to host conference call on May 16, 2017 at...
Minerva Announces Outcome of End-of-Phase 2 Meeting With FDA
15 mai 2017 08h00 HE
|
Minerva Neurosciences, Inc.
Pivotal Phase 3 trial design to include monotherapy administration of MIN-101 and primary endpoint of improvement in negative symptoms of schizophrenia Planned initiation of MIN-101 Phase 3...